Literature DB >> 29456160

Hypercholinergic activity in LRRK2 Parkinson's disease.

Nicolaas I Bohnen1, Roger L Albin2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29456160      PMCID： PMC5858987          DOI： 10.1016/S1474-4422(18)30073-5

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  8 in total

1.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.

Authors:  John R Adams; Hinke van Netten; Michael Schulzer; Edwin Mak; Jessamyn Mckenzie; Audrey Strongosky; Vesna Sossi; Thomas J Ruth; Chong S Lee; Matthew Farrer; Thomas Gasser; Ryan J Uitti; Donald B Calne; Zbigniew K Wszolek; A Jon Stoessl
Journal:  Brain       Date:  2005-08-04       Impact factor: 13.501

2.  Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Authors:  Lorraine V Kalia; Anthony E Lang; Lili-Naz Hazrati; Shinsuke Fujioka; Zbigniew K Wszolek; Dennis W Dickson; Owen A Ross; Vivianna M Van Deerlin; John Q Trojanowski; Howard I Hurtig; Roy N Alcalay; Karen S Marder; Lorraine N Clark; Carles Gaig; Eduardo Tolosa; Javier Ruiz-Martínez; Jose F Marti-Masso; Isidre Ferrer; Adolfo López de Munain; Samuel M Goldman; Birgitt Schüle; J William Langston; Jan O Aasly; Maria T Giordana; Vincenzo Bonifati; Andreas Puschmann; Margherita Canesi; Gianni Pezzoli; Andre Maues De Paula; Kazuko Hasegawa; Charles Duyckaerts; Alexis Brice; A Jon Stoessl; Connie Marras
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

3.  The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.

Authors:  Claustre Pont-Sunyer; Eduardo Tolosa; Chelsea Caspell-Garcia; Christopher Coffey; Roy N Alcalay; Piu Chan; John E Duda; Maurizio Facheris; Rubén Fernández-Santiago; Kenneth Marek; Francisco Lomeña; Connie Marras; Elisabet Mondragon; Rachel Saunders-Pullman; Bjorg Waro
Journal:  Mov Disord       Date:  2017-03-28       Impact factor: 10.338

4.  Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

Authors:  Steven T DeKosky; Milos D Ikonomovic; Scot D Styren; Laurel Beckett; Stephen Wisniewski; David A Bennett; Elizabeth J Cochran; Jeffrey H Kordower; Elliott J Mufson
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

Review 5.  Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.

Authors:  Martin Sarter; Roger L Albin; Aaron Kucinski; Cindy Lustig
Journal:  Exp Neurol       Date:  2014-05-05       Impact factor: 5.330

6.  The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.

Authors:  Shu-Ying Liu; Daryl J Wile; Jessie Fanglu Fu; Jason Valerio; Elham Shahinfard; Siobhan McCormick; Rostom Mabrouk; Nasim Vafai; Jess McKenzie; Nicole Neilson; Alexandra Perez-Soriano; Julieta E Arena; Mariya Cherkasova; Piu Chan; Jing Zhang; Cyrus P Zabetian; Jan O Aasly; Zbigniew K Wszolek; Martin J McKeown; Michael J Adam; Thomas J Ruth; Michael Schulzer; Vesna Sossi; A Jon Stoessl
Journal:  Lancet Neurol       Date:  2018-02-16       Impact factor: 44.182

Review 7.  Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems.

Authors:  D Carnevale; R De Simone; L Minghetti
Journal:  CNS Neurol Disord Drug Targets       Date:  2007-12       Impact factor: 4.388

Review 8.  Cholinergic dysfunction in Parkinson's disease.

Authors:  Martijn L T M Müller; Nicolaas I Bohnen
Journal:  Curr Neurol Neurosci Rep       Date:  2013-09       Impact factor: 5.081
  8 in total
  1 in total

Review 1.  The Cholinergic Brain in Parkinson's Disease.

Authors:  Jacopo Pasquini; David J Brooks; Nicola Pavese
Journal:  Mov Disord Clin Pract       Date:  2021-08-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.